Management of hypertension in CAH should prioritize angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) due to their cardioprotective properties, beneficial effects on endothelial function, and ability to improve insulin sensitivity (321, 322). This evidence concerns the gene ACE and congenital adrenal hyperplasia.